# 2025-15797: Optimizing Nuke Doses for Cancer Drugs: FDA's Latest Tip Sheet

2025-15797, Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-08-19 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-15797
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-15797
- Title: Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 40370
- Published: 2025-08-19
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

Optimizing Nuke Doses for Cancer Drugs: FDA's Latest Tip Sheet

## Summary

The FDA just dropped a draft guide to help drug makers find the best doses for cancer-fighting radiopharmaceuticals during testing. This means companies can develop safer, more effective treatments before asking to sell them. If you’re in the cancer drug game, this guide is your new playbook—expect smoother approvals and smarter dosing decisions soon!

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development." This guidance is intended to assist sponsors in identifying an optimized dosage for radiopharmaceutical therapies (RPT) for oncology indications during clinical development and prior to submitting a marketing application for a new indication and usage. The guidance provides considerations for RPT dosage optimization in RPT development programs.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2025-15797 on federalregister.gov](https://www.federalregister.gov/documents/2025/08/19/2025-15797/oncology-therapeutic-radiopharmaceuticals-dosage-optimization-during-clinical-development-draft)
- [2025-15797 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-08-19/pdf/2025-15797.pdf)

## Related
- [Previous: 2025-15796, Approaches to Assessment of Overall Survival in Oncology Clinical Trials; Draft…](https://policyrisk.com/federal-register/2025-15796)
- [Next: 2025-15798, National Institute of Environmental Health Sciences; Notice of Meeting](https://policyrisk.com/federal-register/2025-15798)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-15797 (as of 2026-06-08).